| Literature DB >> 28781988 |
Michael Lehrer1, Anindya Bhadra2, Visweswaran Ravikumar1, James Y Chen3,4, Max Wintermark5, Scott N Hwang6, Chad A Holder7, Erich P Huang8, Brenda Fevrier-Sullivan9, John B Freymann9, Arvind Rao1.
Abstract
BACKGROUND ANDEntities:
Keywords: imaging-proteomics analysis; lower grade glioma; multiple-response regression; radiomics; signaling pathway activity
Year: 2017 PMID: 28781988 PMCID: PMC5538849 DOI: 10.18632/oncoscience.353
Source DB: PubMed Journal: Oncoscience ISSN: 2331-4737
Patient demographic information
| Mean Age at Diagnosis (Range) | 47.2 (22 - 70) |
| Gender - M/F | 24/33 |
| Median Overall Survival (Months) | 23.3 |
| Median Disease-Free Survival (Months) | 23.3 |
| Oligodendroglioma/Astrocytoma/Oligoastrocytoma | 25/13/18 |
| Mean KPS (Range) | 89.5 (50 - 100) |
Demographics are given for the 57 patients included in this study.
Radiological features are associated with unique pathway alterations in LGG
| T1/FLAIR ratio | Acute Myeloid Leukemia Signaling 6.651, Cancer Drug Resistance by Drug Efflux 5.48, AMPK Signaling 5.38 |
| MRI Necrosis | Cancer Drug Resistance by Drug Efflux 8.968, PI3K/AKT Signaling 8.738 14-3-3-mediated Signaling 8.614 |
| Leptomeningeal reaction | Neuregulin Signaling 15.714, Acute Myeloid Leukemia Signaling 11.297 ErbB Signaling 11.067 |
| Cross-product length | Glucocorticoid Receptor Signaling 3.879, IL-2 Signaling 3.602, ErbB2-ErbB3 Signaling 3.537 |
| Enhancing tumor | Molecular Mechanisms of Cancer 3.505, GADD45 Signaling 2.745, DNA damage-induced 14-3-3Ï |
| Enhancing cortical involvement | ATM Signaling 3.408, Hereditary Breast Cancer Signaling 2.912, ILK Signaling 2.636 |
| Mild enhancement quality | 14-3-3-mediated Signaling 6.36, Aryl Hydrocarbon Receptor Signaling 6.231, AMPK Signaling 5.71 |
| Edema | Neuregulin Signaling 15.666, Glioblastoma Multiforme Signaling 14.801, Role of Tissue Factor in Cancer 14.2 |
| Definition of the non-enhancing margin | AMPK Signaling 3.326, Glucocorticoid Receptor Signaling 2.965, Notch signaling 2.144 |
| Definition of the enhancing margin | VEGF Signaling 4.62, PI3K/AKT Signaling 4.379, Molecular Mechanisms of Cancer 4.369 |
| Cysts present | Molecular Mechanisms of Cancer 8.654, Glioblastoma Multiforme Signaling 8.568, AMPK Signaling 8.046 |
| Tumor localization in the parietal lobe | HER-2 Signaling in Breast Cancer 8.177, ErbB Signaling 7.94, Pancreatic Adenocarcinoma Signaling 7.533 |
| Tumor localization to the frontal lobe | UVB-Induced MAPK Signaling 2.205, FLT3 Signaling in Hematopoietic Progenitor Cells 2.095, Role of Tissue Factor in Cancer 1.94 |
Proteins with expression significantly correlated with imaging features were analyzed by IPA. Top pathways for each feature are shown with the associated –log (p-value).
Figure 1Agglomerative unsupervised hierarchical clustering of Ingenuity Pathway Analysis p-values and Z-activation scores associated with each VASARI features and IPA Canonical Pathways reveal a subset highly-correlated with pathway alterations
A heat map of a representative subset of the results of the clustering of the p-values (A) and Z-activation scores (B) calculated in IPA for each imaging feature and IPA canonical pathway are shown.
Figure 2Agglomerative unsupervised hierarchical clustering of Ingenuity Pathway Analysis p-values and Z-activation scores associated with each VASARI features and IPA Diseases and Bio-functions correlated with biological dysfunction
A heat map of a representative subset of the results of the clustering of the p-values (A) and Z-activation scores (B) calculated in IPA for each imaging feature and IPA diseases and bio-functions are shown.
Figure 3Representative axial MR T1, T1 gadolinium contrast enhanced, fluid-attenuation recovery, and T2-weighted acquisitions with corresponding VASARI scores
Scores for the VASARI feature set for a representative set of MR scans are shown. MR sequences are downloaded from The Cancer Imaging Archive [47].